vTv Therapeutics(VTVT) - 2025 Q2 - Quarterly Results

Exhibit 99.1 vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update • Leadership team strengthened HIGH POINT, N.C., August 12, 2025 (GLOBE NEWSWIRE) – vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2025 ...